Overview

Multicentric randomised trial. The goal of this clinical research study is to evaluate the efficacy and safety of serplulimab combined with FOLFIRI+bevacizumab in the treatment of pMMR/Ras/BRAF wild-type unresectable peritoneal metastasis of colon cancer.

Eligibility

Inclusion Criteria:

• 1. Colon cancer was confirmed by histology, and its gene detection was pMMR/MSS and RAS/BRAF wild-type. Imaging showed peritoneal metastasis.
• 2. Peritoneal metastatic carcinoma that could not reach CC0/1 was detected surgically.
• 3. Patients with the following general characteristics:
  1. Age between 18 and 75 years
  2. Performance Status (ECOG) 0, 1 or 2, life expectancy > 12 weeks
  3. Adequate renal, and bone marrow function: a. Leukocytes >/= 3,000/microL; b. Absolute neutrophil count >/= 1,500/microL; c. Platelets >/= 100,000/Ul; d. Serum creatinine </= 1.5 mg/dL
• 4. Hepatic function: AST (SGOT)/ALT (SGPT) </= 5 X institutional (Upper Limit of

  Normal) ULN.

• 5. Able to tolerate immunotherapy, chemotherapy and surgery.
• 6. Patients will be informed and a signed consent before initiating any procedure specific to the trial.

Exclusion Criteria:

• 1. Age >75years or age<18years.
• 2. Cancers of non colonic origin.
• 3. History of cancer (excepted cutaneous basal cell carcinoma or in situ carcinoma of the uterine cervix) with a recurrence during the 5 previous years.
• 4. Known HIV, Hepatitis B or Hepatitis C positive.
• 5. Pregnant women or likely to be pregnant.
• 6. Persons under guardianship.
• 7. Subjects deemed unable to comply with study and/or follow-up procedures.
• 8. Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity